Tauriga Sciences (OTCMKTS:TAUG) and NeuroOne Medical Technologies (NASDAQ:NMTC) Head to Head Review

Tauriga Sciences (OTCMKTS:TAUG) and NeuroOne Medical Technologies (NASDAQ:NMTC) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

Analyst Recommendations

This is a breakdown of current recommendations for Tauriga Sciences and NeuroOne Medical Technologies, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tauriga Sciences	0	0	0	0	0.00
NeuroOne Medical Technologies	1	1	3	0	2.40

NeuroOne Medical Technologies has a consensus target price of $11.67, indicating a potential upside of 283.77%. Given NeuroOne Medical Technologies’ stronger consensus rating and higher possible upside, analysts plainly believe NeuroOne Medical Technologies is more favorable than Tauriga Sciences.

Institutional and Insider Ownership

16.1% of NeuroOne Medical Technologies shares are held by institutional investors. 3.5% of Tauriga Sciences shares are held by company insiders. Comparatively, 11.8% of NeuroOne Medical Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Tauriga Sciences and NeuroOne Medical Technologies”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tauriga Sciences	N/A	N/A	N/A	N/A	N/A
NeuroOne Medical Technologies	$12.10 million	2.19	-$3.61 million	($0.85)	-3.58

Tauriga Sciences has higher earnings, but lower revenue than NeuroOne Medical Technologies.

Profitability

This table compares Tauriga Sciences and NeuroOne Medical Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tauriga Sciences	N/A	N/A	N/A
NeuroOne Medical Technologies	-68.35%	-99.43%	-70.40%

Summary

NeuroOne Medical Technologies beats Tauriga Sciences on 6 of the 9 factors compared between the two stocks.

About Tauriga Sciences

Tauriga Sciences, Inc. produces and sells cannabidiol infused chewing gum under the Tauri-Gum brand name. It also develops anti-nausea products; and skin care products include CBD facemasks; CBD daily moisturizer; CBD anti-wrinkle dream, hand, and foot cream with hemp seed oil; CBD massage and body oil; CBD body revive roll-on; CBD transdermal patch; and CBD body spray. In addition, the company offers rainbow deluxe sampler pack, CBD non-GMO dietary supplements, and CBD scented bath bombs. It sells its products through e-commerce, distributors, and wholesale channels. The company has a collaboration agreement with Aegea Biotechnologies, Inc. to develop a rapid, multiplexed COVID-19 (novel coronavirus) test. Tauriga Sciences, Inc. was founded in 2001 and is headquartered in Wappingers Falls, New York.

About NeuroOne Medical Technologies

NeuroOne Medical Technologies Corporation, a developmental stage company, provides solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other related neurological disorders. It also fucuses on applications for other areas, such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator. The company was incorporated in 2009 and is based in Eden Prairie, Minnesota.